About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 491 record(s)
Req # A-2023-000826
Health Canada currently has two generic submissions under review for the drug Eplerenone. The following information for these submissions: Date of application Manufacturer or Company Class, Product type Submission type Canadian reference product…Organization: Health Canada
November 2023
Req # A-2023-000883
The briefing book prepared by the Department for the incoming new Minister of Health, Mark Holland following the recent cabinet shuffle.Organization: Health Canada
November 2023
Req # A-2020-001112
Adverse Drug Reactions (ADRs). Report numbers: E2B_02074491, E2B_02075650, E2B_02076081, E2B_02076428, E2B_02077572, E2B_02077995, E2B_02078001, E2B_02081073, E2B_02082449, E2B_02084090, E2B_02088710, E2B_02091938, E2B_02094774, E2B_02095027,…Organization: Health Canada
November 2023
Req # A-2020-001215
Adverse Drug Reactions (ADRs). Report numbers: E2B_02499311, E2B_02499388, E2B_02499863, E2B_02500524, E2B_02501051, E2B_02501996, E2B_02502002, E2B_02502004, E2B_02502019, E2B_02502112, E2B_02502123, E2B_02502174, E2B_02502200, E2B_02502201,…Organization: Health Canada
November 2023
Req # A-2020-001363
Adverse Drug Reactions (ADRs). Report numbers: E2B_02759984, E2B_02759991, E2B_02759992, E2B_02759993, E2B_02759995, E2B_02759999, E2B_02760000, E2B_02760008, E2B_02760014, E2B_02760016, E2B_02760018, E2B_02760028, E2B_02760052, E2B_02760062,…Organization: Health Canada
November 2023
Req # A-2020-001398
Adverse Drug Reactions (ADRs). Report numbers: E2B_02923744, E2B_02923770, E2B_02923787, E2B_02923791, E2B_02923797, E2B_02923798, E2B_02924527, E2B_02924704, E2B_02924958, E2B_02925846, E2B_02926149, E2B_02926635, E2B_02926636, E2B_02927181,…Organization: Health Canada
November 2023
Req # A-2021-000111
Adverse Drug Reactions (ADRs) for Cipralex. Report numbers: 913781, E2B_03222881, E2B_03209564, 914535, 913955, E2B_03201921, E2B_03242954, E2B_03260823 , E2B_03230378, 916963, 919987, E2B_03321958, 920020.Organization: Health Canada
November 2023
Req # A-2021-000439
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-100121-662.Organization: Health Canada
November 2023
Req # A-2021-001029
Adverse Drug Reactions (ADRs). Report numbers: E2B_01899783, E2B_01918621, E2B_01958799, E2B_01983423, E2B_02123327, E2B_02125660, E2B_02183567, E2B_02201561, E2B_02260351, E2B_02230110, E2B_02229967.Organization: Health Canada
November 2023
Req # A-2021-001151
Adverse Drug Reactions (ADRs) for WHITE PETROLATUM. Report numbers: E2B_03905714, E2B_03905715.Organization: Health Canada
November 2023